

NEWS RELEASE

RECORDATI: PUBLIC DISCLOSURE

Milan, 30th July 2021 – Following the press release issued on date 29th July 2021, please be informed that the Interim financial statements at 30th June 2021, approved yesterday by the Board of Directors, and the Independent Auditors' Report on the interim condensed consolidated financial statements at 30th June 2021 are available to the public, as of today, at the Company's registered office, on the Company's website (www.recordati.com) and on the "1INFO" storage mechanism (www.linfo.it).

Recordati (Reuters RECI.MI, Bloomberg REC IM), established in 1926, is an international pharmaceutical group listed on the Italian Stock Exchange (ISIN IT 0003828271), with a total staff of more than 4,300, dedicated to the research, development, manufacturing and marketing of pharmaceuticals. Headquartered in Milan, Italy, Recordati has operations in Europe, Russia and other countries of the CIS, Ukraine, Turkey, North Africa, the United States, Canada, Mexico, some South American countries, Japan and Australia. An efficient field force of medical representatives promotes a wide range of innovative pharmaceuticals, both proprietary and under licence, from a number of therapeutic areas, including a specialised business dedicated to rare diseases. Recordati is a partner of choice for new product licences for its territories. Recordati is committed to the research and development of new specialties with a focus on treatments for rare diseases. Consolidated revenue for 2020 was €1,448.9 million, operating income was €469.0 million and net income was €355.0 million.

Further information:

Recordati website: www.recordati.it

Investor Relations
Federica De Medici
(39) 02 48787146

e-mail: investorelations@recordati.it

Media Relations

Studio Noris Morano

(39) 02 76004736, (39) 02 76004745

e-mail: norismorano@studionorismorano.com

RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.p.A.

TEL. +39 0248787.1 00748210150 FAX +39 0240073747 TAX CODE/VAT NO. 00748210150